|
Obesity
|
0.230 |
Biomarker
|
disease |
BEFREE |
Agouti signaling protein (ASP) is a secreted paracrine protein that has been widely reported to function in melanogenesis and obesity and could potentially be a core protein that regulates the color and fatty phenotype of P. sinensis.
|
31794826 |
2019 |
|
Malignant mesothelioma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Therefore, ASP and METRNL potentially could be used as markers for differentiating MM from benign diseases.
|
31570005 |
2020 |
|
Pancreatitis
|
0.010 |
Biomarker
|
disease |
BEFREE |
It is known, that ASP can cause several toxicities such as hypersensitivity, pancreatitis, as well as severe lipid and coagulation disturbances.
|
31515171 |
2019 |
|
Myocardial Infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
We investigated the role of ASP on MSCs and the effects of ASP-pretreated MSCs on myocardial infarction (MI).
|
31194992 |
2019 |
|
Myocardial Ischemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
This is the first evidence that ASP can regulate MSCs function and enhance MSCs therapy for ischemic heart disease.
|
31194992 |
2019 |
|
Clostridium difficile infection
|
0.010 |
Biomarker
|
disease |
BEFREE |
We evaluated whether a diagnostic stewardship initiative consisting of ASP preauthorization paired with education could reduce false-positive hospital-onset (HO) Clostridioides difficile infection (CDI).
|
30786942 |
2019 |
|
Central Diabetes Insipidus
|
0.010 |
Biomarker
|
disease |
BEFREE |
We evaluated whether a diagnostic stewardship initiative consisting of ASP preauthorization paired with education could reduce false-positive hospital-onset (HO) Clostridioides difficile infection (CDI).
|
30786942 |
2019 |
|
Alzheimer's Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
In the logistic regression analysis, PCho, GPCho, ASP, and α&β-Glc were found to be the most relevant metabolites for differentiating the AD patient tissues and the controls, and different APOE genotypes.
|
30687076 |
2018 |
|
Malignant neoplasm of breast
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Allele-specific Primer PCR (ASP-PCR) was recruited in this study to genotype rs13423759 position in 172 breast cancer and 148 healthy control subjects.
|
30336339 |
2018 |
|
Breast Carcinoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Allele-specific Primer PCR (ASP-PCR) was recruited in this study to genotype rs13423759 position in 172 breast cancer and 148 healthy control subjects.
|
30336339 |
2018 |
|
Kluver-Bucy Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
We report the case of ASP, a patient who developed a complete KBS at 9 years that evolved into an incomplete KBS.
|
30247092 |
2018 |
|
Blood Protein Measurement
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Genomic atlas of the human plasma proteome.
|
29875488 |
2018 |
|
Rheumatoid Arthritis
|
0.020 |
Biomarker
|
disease |
BEFREE |
We studied 393 patients with rheumatic diseases, including ankylosing spondylitis (ASP, n = 90), rheumatoid arthritis (RA; n = 120), psoriatic arthritis (PA, n = 126), and other disorders (n = 57).
|
29735171 |
2018 |
|
Arthritis, Psoriatic
|
0.010 |
Biomarker
|
disease |
BEFREE |
We studied 393 patients with rheumatic diseases, including ankylosing spondylitis (ASP, n = 90), rheumatoid arthritis (RA; n = 120), psoriatic arthritis (PA, n = 126), and other disorders (n = 57).
|
29735171 |
2018 |
|
Ankylosing spondylitis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We studied 393 patients with rheumatic diseases, including ankylosing spondylitis (ASP, n = 90), rheumatoid arthritis (RA; n = 120), psoriatic arthritis (PA, n = 126), and other disorders (n = 57).
|
29735171 |
2018 |
|
Acute lymphocytic leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to investigate the growth inhibition effects of GA in combination with asparaginase (ASP), as a component of combination chemotherapy, in a lymphoblastic leukemia cell line.
|
29217160 |
2017 |
|
Lymphoid leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to investigate the growth inhibition effects of GA in combination with asparaginase (ASP), as a component of combination chemotherapy, in a lymphoblastic leukemia cell line.
|
29217160 |
2017 |
|
Precursor Cell Lymphoblastic Leukemia Lymphoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
The aim of the present study was to investigate the growth inhibition effects of GA in combination with asparaginase (ASP), as a component of combination chemotherapy, in a lymphoblastic leukemia cell line.
|
29217160 |
2017 |
|
Acute lymphocytic leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL.
|
29165013 |
2018 |
|
Childhood Acute Lymphoblastic Leukemia
|
0.060 |
Biomarker
|
disease |
BEFREE |
Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL.
|
29165013 |
2018 |
|
Adult Acute Lymphocytic Leukemia
|
0.040 |
Biomarker
|
disease |
BEFREE |
Native vs. PEG-ASP administered according to availability in each center were prospectively evaluated in adults with high-risk ALL.
|
29165013 |
2018 |
|
Malignant Neoplasms
|
0.210 |
Biomarker
|
group |
BEFREE |
These results implied that AS1041 was a novel derivative of ASP-A with significant cytotoxicity to chronic myelogenous leukemia cells and may have therapeutic potential for the treatment of cancer and leukemia.
|
29113054 |
2017 |
|
Primary malignant neoplasm
|
0.010 |
Biomarker
|
group |
BEFREE |
These results implied that AS1041 was a novel derivative of ASP-A with significant cytotoxicity to chronic myelogenous leukemia cells and may have therapeutic potential for the treatment of cancer and leukemia.
|
29113054 |
2017 |
|
Xeroderma Pigmentosum
|
0.010 |
Biomarker
|
disease |
BEFREE |
MC1R antagonists human beta-defensin 3 and agouti signaling protein blocked MSH- but not forskolin-mediated enhancement of platinum-induced DNA damage. cAMP-enhanced repair of cisplatin-induced DNA damage was dependent on PKA-mediated phosphorylation of ATR on S435 which promoted ATR's interaction with the key NER factor xeroderma pigmentosum A (XPA) and facilitated recruitment of an XPA-ATR-pS435 complex to sites of cisplatin DNA damage.
|
28916831 |
2017 |
|
Intraocular Lymphoma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A total of 105 patients (210 eyes) were divided into three groups according to the type of IOLs: ZA9003 (35 patients, 70 eyes), MCX11 ASP (35 patients, 70 eyes) or HQ-201HEP (35 patients, 70 eyes).
|
28870348 |
2017 |